bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD
bioAffinity Technologies (Nasdaq: BIAF) said it will partner with Pictor, Inc. to develop and commercialize next-generation asthma and COPD diagnostics. The collaboration combines bioAffinity flow cytometry with Pictor targeted proteomic cytokine profiling, with tests expected to launch as CLIA Laboratory Developed Tests. bioAffinity will own IP for the tests; Pictor retains its platform IP.
How this was made
The 30-second read
Why it matters
The collaboration combines bioAffinity’s flow cytometry immune-cell quantification with Pictor’s targeted proteomic cytokine profiling to create high-throughput LDTs under CLIA, aiming to support precision medicine and biologic selection.
Market read
A new partnership expands bioAffinity’s lung diagnostics pipeline into asthma and COPD, with an LDT commercialization path and IP ownership structure, but no quantified financial impact.
What to watch
Key execution risks include LDT adoption hurdles, payer/provider reimbursement dynamics for asthma/COPD diagnostics, and whether the integrated flow cytometry plus cytokine profiling yields clear clinical utility versus existing biomarkers.
Background
bioAffinity’s existing lung platform (sputum analysis) powers its CyPath Lung LDT, and this collaboration extends that approach into asthma and COPD inflammatory pathway profiling.
Ticker impact
bioAffinity announced a collaboration with Pictor to develop and commercialize its asthma and COPD diagnostic tests using flow cytometry plus targeted proteomics.
Near-term reaction likely modest to moderate, driven by deal validation and market potential framing rather than immediate revenue visibility.
The article discloses a new partnership and intended test pathway (LDT under CLIA) plus IP ownership details, but provides no timelines, trial results, regulatory milestones, or deal economics that would materially reprice near-term cash flows.
Market effects
Supports the broader targeted diagnostics and proteomics workflow trend, potentially increasing competitive attention on multi-analyte, high-throughput lab-developed testing.
No specific regional market impact beyond US lab commercialization framing.
Asthma/COPD prevalence and global market sizing are cited, but the partnership itself is not tied to a specific geography beyond Pictor’s operations.
Counterpoint
Without disclosed clinical performance data, timelines, or commercial terms, the partnership may not translate into revenue quickly, limiting upside versus valuation expectations.
Key entities
- companybioAffinity Technologies, Inc.
Nasdaq-listed diagnostics company developing noninvasive lung tests; announced the Pictor collaboration for asthma and COPD diagnostics.
- companyPictor, Inc.
Targeted proteomic platform company providing cytokine profiling and related workflow/IP for the collaboration.
- productCyPath Lung
bioAffinity’s commercially available noninvasive LDT for pulmonary nodule malignancy likelihood, based on the same sputum analysis platform.
